Navneet Singh, A Thoracic Medical Oncologist and a Professor at PGIMER, shared an article on LinkedIn:
“With Megan Daly and Nofisat Ismaila,
Molecular testing especially EGFR and ALK now has a role in all stages of NSCLC for selection of patients for respective targeted drugs. Similarly for NSCLC without EGFR and ALK [& most other targetable oncogenic driver alterations], immunotherapy with PD-(L)1 immune checkpoint inhibitors has a role in all disease stages.”
Authors: Navneet Singh, et al.
Dr. Navneet Singh, a thoracic medical oncologist and a professor at PGIMER, Chandigarh, specializes in non-small cell lung cancer (NSCLC) treatment, focusing on targeted therapies and immunotherapy. He leads PGIMER’s thoracic oncology group, which won the Lung Cancer Care Team Award at the 2019 WCLC. Dr. Singh received the prestigious Clifton Mountain Lectureship Award in 2023. With over 200 publications, he’s contributed significantly to the field, serving on various committees and earning ASCO’s IDEA and FASCO awards.
